
CORONA
CORONA REMEDIES LIMITED
- IPO Status
- Closed
- Open Date
- 8 Dec 2025
- Close Date
- 10 Dec 2025
IPO Details
- Min. Investment
- ₹14,868
- Price Band
- ₹1008 - ₹1062
- Lot Size
- 14 shares
- Issue Size
- ₹655 Cr
- Face Value
- 10
- IPO Doc
- —
Schedule
- IPO open8 Dec 2025
- IPO close date10 Dec 2025
- Allotment date11 Dec 2025
- Funds unblock or debit12 Dec 2025
- Listing date15 Dec 2025
Financial Performance
- Revenue
- Profit
Stocks similar to CORONA
- Abbott India Ltd
- Alkem Laboratories Ltd
- ERIS Lifesciences Ltd
- Glaxosmithkline Pharmaceuticals Ltd
- Mankind Pharma Ltd
- Pfizer Ltd
- Sanofi India Ltd
- Torrent Pharmaceuticals Ltd
FAQs
CORONA REMEDIES LIMITED IPO is a Mainboard IPO aggregating up to ₹655 Cr, with equity shares of face value ₹10 each. The shares are proposed to be listed on NSE.
The CORONA REMEDIES LIMITED IPO opened on 8 Dec 2025 and closed on 10 Dec 2025. IPO Period: 8 Dec 2025 – 10 Dec 2025.
The price band for the CORONA REMEDIES LIMITED IPO is ₹1,008 to ₹1,062 per share. Investors can bid within the specified price band, subject to the applicable IPO rules.
The minimum lot size is 14 shares. At the upper price band of ₹1,062, the minimum investment required is ₹14,868.
Particular Details Lot Size 14 shares Price Band ₹1,008 – ₹1,062 Minimum Investment ₹14,868 Maximum Retail Lots 13 Here is the timeline for the CORONA REMEDIES LIMITED IPO:
IPO Event Date IPO Opens 8 Dec 2025 IPO Closes 10 Dec 2025 UPI Mandate Deadline 10 Dec 2025, 5:00 PM Basis of Allotment 11 Dec 2025 Refund Initiation 12 Dec 2025 Shares Credited 12 Dec 2025 Listing Date 15 Dec 2025 The basis of allotment for the CORONA REMEDIES LIMITED IPO is expected to be finalised on 11 Dec 2025. Investors can check their allotment status through the registrar or relevant stock exchange website using their application details. Registrar: Bigshare Services.
The equity shares of CORONA REMEDIES LIMITED are proposed to be listed on NSE. Proposed Listing Date: 15 Dec 2025.
The key financial performance of CORONA REMEDIES LIMITED is:
Financial Year Revenue Profit FY24 ₹1,014.47 Cr ₹90.5 Cr FY25 ₹1,196.42 Cr ₹149.43 Cr FY26 ₹1,403.18 Cr ₹185.12 Cr Revenue CAGR: 17.6% | Profit CAGR: 43%. Figures are as disclosed in the company's offer documents.


